Viatris (VTRS) share buybacks: $500M
Viatris spent $500M buying back its own shares in the year ended Dec 31, 2025, up 100.2% from $250M a year earlier.
From Viatris's filings with the SEC · Read the filing · VTRS stock page
Viatris share buybacks by year
#361 of 1,890 US companies by share buybacks · See the full ranking
| Year ended | Share buybacks | Change |
|---|---|---|
| Dec 31, 2025 | $500M | +100% |
| Dec 31, 2024 | $250M | No change |
| Dec 31, 2023 | $250M | – |
Share buybacks of similar companies
Companies in the same industry as Viatris, by SEC industry code, with the closest share buybacks. Each name opens the same page for that company.
| Company | Share buybacks, latest year | Year ended |
|---|---|---|
| Royalty Pharma | $1.2B | Dec 31, 2025 |
| United Therapeutics | $1B | Dec 31, 2025 |
| AbbVie | $980M | Dec 31, 2025 |
| Abbott Laboratories | $893M | Dec 31, 2025 |
| Viatris | $500M | Dec 31, 2025 |
| Corcept Therapeutics | $173M | Dec 31, 2025 |
| Prestige Consumer Healthcare | $156M | Mar 31, 2026 |
Questions and answers
What is Viatris's share buybacks?
Viatris spent $500M buying back its own shares in the year ended Dec 31, 2025, up 100.2% from $250M a year earlier.
Numbers as reported in Viatris's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology